RSS

Eisai

Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Interim results from the advanced renal cell carcinoma (RCC) cohort of a study evaluating Kisplyx (lenvatinib) in combination with Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA), have been announced by Eisai. more

News

Global research and development-based pharmaceutical company, Eisai, has submitted a marketing authorization application to the European Medicines Agency (EMA) for its first-line hepatocellular carcinoma treatment, lenvatinib. more

News

The European Medicines Agency (EMA) has approved Zebinix (eslicarbazepine acetate) for use as once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy. more

News

A quick review of some recent treatment approvals, clinical studies and general news in curing diseases, affecting patients from top to bottom. more

News

Kancera reports positive effects demonstrated with its substance, KAND567, in blocking the Fractalkine system. more

News

Zebinix, an anti-epileptic drug which is used as an add-on therapy for adult patients with partial-onset seizures has been shown to reduce seizure frequency. more

News

Eisai has announced the initiation of a new trial designed to evaluate the efficacy of a combined therapy for patients suffering from advanced kidney cancer. more

Lenvatinib, discovered and developed by Eisai, has been submitted for review by the European Medicines Agency (EMA) for use in combination with everolimus to treat people with metastatic kidney cancer more

News